About Emicizumab (HEMLIBRA)
Class: | Monoclonal antibody (bispecific)
Use: | Prophylaxis of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency) who have inhibitors to factor VIII
Adult dose: | 3 mg/kg subcutaneously once weekly, or 1.5 mg/kg subcutaneously every 2 weeks, or 6 mg/kg subcutaneously once every 4 weeks
Pediatric dose: | For patients weighing less than 40 kg: 3 mg/kg subcutaneously once weekly, or 1.5 mg/kg subcutaneously every 2 weeks; for patients weighing 40 kg or more,
Drug Class
Monoclonal antibody (bispecific)
Uses & Indications
Prophylaxis of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency) who have inhibitors to factor VIII
Storage Requirements
Store in the refrigerator at 2°C to 8°C (36°F to 46°F); do not freeze; may be stored at room temperature (up to 30°C or 86°F) for up to 7 days
Manufacturer & Packaging
Manufacturer: F. Hoffmann-La Roche Ltd., SWITZERLAND
Package Size
1 Vial
Price & Supplier
Price in UAE: AED 10899.50
Dosage Information
Adult Dose
3 mg/kg subcutaneously once weekly, or 1.5 mg/kg subcutaneously every 2 weeks, or 6 mg/kg subcutaneously once every 4 weeks
Pediatric Dose
For patients weighing less than 40 kg: 3 mg/kg subcutaneously once weekly, or 1.5 mg/kg subcutaneously every 2 weeks; for patients weighing 40 kg or more, the adult dosing regimen applies
Side Effects
Injection site reactions, headache, arthralgia, nausea, fatigue, and increased risk of thrombotic microangiopathy (TMA)
Contraindications & Precautions
History of serious allergic reactions to emicizumab or any component of the formulation; caution in patients with a history of thrombotic events
Important Warnings
Risk of thrombotic microangiopathy (TMA) and thromboembolic events; monitor for signs and symptoms of TMA; not indicated for the treatment of bleeding episodes; ensure appropriate factor replacement therapy is available if needed
Related Medicines in Same Category
See also: Other Monoclonal antibody (bispecific) medicines available in UAE pharmacies
Emicizumab
Emicizumab
Emicizumab
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice.
Always consult with a licensed healthcare provider or pharmacist in the UAE before taking any medication.
The information presented here is specific to medicines available in UAE pharmacies and is regularly updated
to ensure accuracy for patients and healthcare professionals in the United Arab Emirates.